Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2019 16:05 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

New Meta-Analysis Data Suggests IV Meloxicam Produces Largest SPID, Greater Reduction in Opioid Use and Better Safety Profile Compared to Other Non-Opioid Medications for Moderate to Severe Pain ...
April 03, 2019 16:05 ET | Source: Recro Pharma, Inc.

Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance

Implements Plan to Reduce Acute Care Segment Staff CDMO Segment Continues Strong Performance; Company Increases Revenue, Operating Income and EBITDA, as Adjusted* Guidance for 2019 Expects to Become...
March 25, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors

MALVERN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
March 22, 2019 15:30 ET | Source: Recro Pharma, Inc.

Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

MALVERN, Pa., March 22, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
March 12, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting

MALVERN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
March 04, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility

MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
February 25, 2019 16:05 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
February 20, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine

MALVERN, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
February 19, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

March 24, 2019 PDUFA Goal Date for IV Meloxicam Record CDMO Performance; 2018 Revenues of $77.3 Million Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Feb. 19, 2019 (GLOBE...
February 14, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019

MALVERN, Pa., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...